Healionics has developed a novel vascular graft, based on a platform biomaterial, offering improved vascular access for dialysis patients.
Healionics has raised $5.5M in total funding. The most recent round was Series A. The last funding was announced in November 2023.
Healionics's investors include Keiretsu Capital, Keiretsu Forum, Rockies Venture Club, Tech Coast Angels, Mid Atlantic Bio Angels.
Healionics is headquartered in Seattle, United States.
Healionics has developed a novel vascular graft, based on a platform biomaterial, offering improved vascular access for dialysis patients.
Healionics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Healionics — Funding & Investors." VCBacked, November 7, 2023, https://www.vcbacked.co/company/healionics. Accessed August 1, 2026.
VCBacked. (2023). Healionics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/healionics
{{cite web |title=Healionics — Funding & Investors |url=https://www.vcbacked.co/company/healionics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated